Filing Flows › Syndax Pharmaceuticals (SNDX) › Q3 2026
Syndax Pharmaceuticals (SNDX) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 2, 2026
Syndax Pharmaceuticals (SNDX) reported revenue of $83.3M for the third quarter 2026 (Q3 2026), +82% from a year earlier and +14% from the quarter before. Operating margin was -50.3%, net loss $49.4M (59.3% of revenue).
Syndax Pharmaceuticals, Q3 2026: revenue $83.3M (+82% year over year), operating margin -50.3%, net loss $49.4M, operating cash flow −$27.3M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $83.3M | +14% | +82% |
| Operating profit | −$41.9M | — | — |
| Net earnings | −$49.4M | — | — |
| Operating cash flow | −$27.3M | — | — |
What changed
Revenue was $83.3M in Q3 2026, up 82% year over year and up 14% from the previous quarter. Product was the largest line at 73% of revenue. Product added $28.7M year over year (up 90%), 77% of the total change.
Operating costs exceeded revenue by $41.9M, an operating margin of -50.3%. Total costs grew 21% against revenue growth of 82%. The fastest-growing cost line was Other operating costs (+566%). The quarter ended with a net loss of $49.4M, wider than the previous quarter's $49.4M loss.
Operating cash flow was −$27.3M. Non-cash charges added back $6.0M of depreciation and $15.3M of share-based compensation.
Questions
What was Syndax Pharmaceuticals' revenue in the third quarter 2026?
Syndax Pharmaceuticals (SNDX) reported revenue of $83.3M for the third quarter 2026 (Q3 2026), +82% from a year earlier and +14% from the quarter before.
Was Syndax Pharmaceuticals profitable in the third quarter 2026?
Operating loss was $41.9M (-50.3% of revenue) and net loss $49.4M.